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1.

Introduction
Sex hormones play an important role in the normal development, growth, and regulation of the prostate [1] . Testosterone has historically been implicated in the pathogenesis of prostate cancer (PCa), although epidemiologic studies generally have not observed an association between circulating androgen levels and risk of developing PCa [2, 3] . In contrast, among men with PCa, studies have found an association between low pretreatment testosterone levels and higher Gleason score [3] [4] [5] , advanced pathologic stage [6] [7] [8] , and positive surgical margins [8] as well as worse overall survival for men diagnosed with metastatic disease [9] [10] [11] . Pretreatment estrogen levels have also been associated with high-grade PCa [12] , and there is evidence that the relationship between sex hormones and high-grade PCa may be nonlinear [13] .
To our knowledge, no study has examined the association between prediagnostic circulating sex hormone levels and clinical outcomes for men with PCa. We conducted this secondary analysis of two large, prospective cohort studies-the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS)-to examine the association of prediagnostic circulating sex hormone levels with lethal PCa and overall survival among men with PCa.
2.
Patients and methods
Study populations
Health Professionals Follow-up Study
The HPFS is an ongoing prospective cohort study of 51 529 US men aged 40-75 yr at enrollment in 1986 and followed with biennial questionnaires described previously [14] . Between 1993 and 1995, 18 018 men provided a blood specimen that was that was stored and used for subsequent analysis.
Physicians' Health Study
The PHS I was a double-blind, placebo-controlled trial that randomized 22 071 healthy US male physicians aged 40-84 yr to either aspirin and/or b-carotene in 1982, as described previously [15] . Prior to randomization, 14 916 men provided a blood sample that was stored and used for subsequent analysis.
Case selection and follow-up
We had biomarker data on 963 participants from the two cohorts (700 in HPFS and 263 in PHS) who were diagnosed with PCa and had provided prediagnostic blood in which circulating sex hormone levels were assayed. Participants in the HPFS were diagnosed between 1993 and 2000, and participants in the PHS were diagnosed between 1982 and 1992. Of the 963 men, 219 (23%) were diagnosed with PCa within 2 yr of blood collection.
Study investigators verified reporting of PCa by review of medical records and pathology reports. Clinical TNM stage was used when pathologic TNM stage was unavailable, and biopsy Gleason score was used when pathologic Gleason score was unavailable. We were able to obtain medical and pathology records for approximately 90% of the HPFS cases and 96% of the PHS cases, with high validity of self-reported diagnosis.
Men were followed from date of cancer diagnosis until death, development of bone or organ metastases, or end of study follow-up (March 2011). Follow-up information was obtained via questionnaires that asked participants to report on treatments and clinical progression.
Medical record review was used to verify report of metastases. Deaths were initially identified either by family member report, via follow-up questionnaire, or through a search of the National Death Index [16] .
Cause of death was centrally verified by study investigators using review of medical records and death certificates.
Laboratory measurements
Frozen blood samples were analyzed as previously described [3, 17] .
Blood samples were stored at À82 8C from blood draw until analyses, and the original samples were aliquoted in multiple vials to minimize freezethaw cycles. Frozen blood samples were shipped on dry ice to the laboratory and assayed for total testosterone, free testosterone (HPFS only), dihydrotestosterone (DHT), androstanediol glucuronide (AAG), sex hormone-binding globulin (SHBG), and estradiol (E2) in a single analytic run in December 1994 for PHS and in three separate analytic runs for HPFS. DHT was unavailable for the third HPFS analytic run, and free testosterone was not measured in the PHS.
Statistical analysis
We calculated batch-specific quartiles for each sex hormone to control for interassay variation. The primary study end point was lethal PCa (defined as cancer-specific mortality or development of metastases), and we also assessed total mortality. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals 
Results
The 963 men with PCa were followed for a mean plus or minus standard deviation of 12.0 AE 4.9 yr after diagnosis ( Table 1) . Mean age at blood draw and diagnosis were 64.7 AE 7.6 yr and 69.1 AE 7.3 yr, respectively. During follow-up, we confirmed 421 deaths overall, 134 deaths due to PCa, and 14 men alive with bone or organ metastases. Deaths due to PCa and men alive with metastatic disease were combined into a single category of lethal PCa (n = 148).
Using Cox proportional hazards models adjusted for age at diagnosis (HR1); further adjusted for BMI, physical activity, and smoking status (HR2); and further adjusted for Gleason score and TNM stage (HR3), we found no significant association between quartile of total testosterone, SHBG, SHBG-adjusted total testosterone, free testosterone, DHT, AAG, or estradiol and lethal PCa or total mortality (Table 2a and 2b). Results were similarly null when age at blood draw was substituted for age at diagnosis in the models as well as when clinical stage and Gleason score at diagnosis were substituted for best available stage or Gleason score (data not shown).
In separate analyses of the HPFS and PHS cohorts, there was no association between any of the sex hormones and lethal PCa or total mortality, with the following exceptions: SHBG-adjusted testosterone in HPFS (HR1 1.00/0.85/0.75/ 0.63, p trend = 0.04 for total mortality), AAG in HPFS (HR3 1.00/1.15/1.10/1.52, p trend = 0.04 for total mortality), and estradiol in HPFS (HR1 1.00/1.58/1.23/2.30, p trend = 0.02; HR2 1.00/1.53/1.26/2.12, p trend = 0.04 for lethal PCa).
Subset analyses were performed on the combined cohort, and in general, we did not see heterogeneity in the results (Table 3) . However, for men with Gleason 8-10 disease, there was an increased risk of lethal PCa with increasing DHT (HR: 1.87; 95% CI, 1.26-2.78). There was also an increased risk of lethal PCa for men with stage T3 disease associated with increasing DHT (HR: 1.98; 95% CI, 1.30-3.00) and SHBG (HR: 1.59; 95% CI, 1.05-2.41), and for men with <2 yr between blood draw and diagnosis associated with increasing DHT (HR: 1.69; 95% CI, 1.17-2.44).
Discussion
In this analysis of two large, prospective PCa cohorts with long-term follow-up, we found no overall association between prediagnostic circulating sex hormone levels and lethal PCa or total mortality. In addition, we did not find any consistent association when men were stratified by age at diagnosis, Gleason score, TNM stage, and time from blood draw to diagnosis, with several exceptions.
To our knowledge, no study has evaluated the relationship between prediagnostic sex hormone levels and clinical outcomes for men with PCa. In contrast, several studies have examined men with metastatic disease and noted an association between lower pretreatment testosterone levels and increased cancer-specific mortality [9, 11, 18, 10] . For example, Ribeiro et al. [11] observed that low pretreatment serum testosterone was associated with a poor response to androgen deprivation therapy. The concept that more aggressive, androgen-independent PCa may develop in a low-androgenicity milieu has also been suggested by other authors [7, 9, 19 ]. An additional study also noted increased biochemical recurrence associated with low pretreatment testosterone in men undergoing radical prostatectomy for localized disease [20] .
There are several obvious differences between these studies and the present one. Most important, these studies used pretreatment testosterone levels (ie, taken at or after diagnosis) rather than prediagnostic levels, and their observations may reflect reverse causality: that low pretreatment testosterone levels are a consequence of PCa itself rather than that aggressive PCa is a result of the hormonal milieu in which it develops. Indeed, several studies have suggested that PCa may result in suppression of circulating total testosterone and free testosterone, noting an increase in these hormones following radical prostatectomy [21] [22] [23] . Such changes are not seen following suprapubic prostatectomy [24] , transurethral resection of the prostate, or for men with PCa on watchful waiting [21] . Moreover, two of these studies [21, 22] noted a concomitant increase in luteinizing hormone and folliclestimulating hormone following radical prostatectomy, suggesting central suppression related to PCa. Interestingly, the glycoprotein inhibin is produced by testis and prostate and has been suggested as a potential inhibitor of pituitary gonadotropins in this setting [22] .
Men with metastatic disease represent a selected subset of all PCa cases, and since primary therapy consists of androgen deprivation, outcomes may be more associated with circulating sex hormone levels than for men with nonmetastatic disease. Interestingly, when we stratified 0 1 4 ) 6 8 3 -6 8 9 patients by TNM stage, we did not observe an association between lethal PCa and any sex hormone for men with T4/N1/M1 disease. This appears to contradict the results of prior studies, and these differences may again be due to the use of prediagnostic rather than pretreatment hormone levels.
Only one small study [25] has previously evaluated the association of circulating DHT with PCa outcomes. In this prospective study, the authors observed a decreased risk of cancer-specific mortality with increasing pretreatment DHT level. Our overall null results contradict these observations. In addition, we noted an increased risk of lethal PCa with increasing DHT level for men diagnosed within 2 yr of blood draw or with Gleason 8-10 disease. As discussed above, the use of prediagnostic rather than pretreatment DHT levels may explain the differing results, as low pretreatment DHT levels may be a consequence of aggressive PCa and not the reverse.
Several studies have observed that higher pretreatment SHBG is associated with worse pathologic outcomes [26, 27] . In contrast, we found no overall relationship between SHBG and lethal PCa, with the exception of patients with T3 disease, in whom higher SHBG was associated with lethal PCa. These differences may be explained by the use of prediagnostic hormone levels or could be due to chance because of the smaller numbers and multiple comparisons.
Other considerations may explain our null results despite biologic plausibility. For instance, circulating sex hormone levels may correlate with potential confounders such as age, BMI [28] , and level of physical activity [29] , all of which were included in our multivariate models but may have confounded results in some prior studies. In addition, some error may be introduced from measuring sex hormone levels at a single time point. Multiple measurements over time would be able to provide a better estimate of long-term exposure or allow us to better assess different etiologic periods of exposure. However, levels of blood sex hormones have been found to have good correlation when measured 3 yr apart [3] . Moreover, the 
results remained consistent when we compared cases diagnosed within 2 yr and >2 yr after diagnosis. This study has several potential limitations. The possibility of residual or unmeasured confounding by comorbid conditions cannot be excluded. Due to the sample size, we did not test for nonlinear associations or use alternate modeling techniques to evaluate for fine associations at the tail ends of the exposure range. Interestingly, a recent study has suggested that the relationship between sex hormones and PCa may be nonlinear [13] . However, we did not observe any evidence of a nonlinear relationship when we categorized the exposures into batch and study-specific quartiles. As with any null study, it is possible that a larger sample size may be required to detect smaller associations.
This study has a number of strengths. It is an analysis of two large, prospective studies with long-term, complete follow-up and excellent ascertainment of centrally verified end points. More importantly, the use of prediagnostic blood samples allows us to examine the association between circulating sex hormone levels and development of lethal PCa, greatly reducing the possibility that changes in hormone levels are a consequence of the cancer itself. Strict quality control measures were in place for the biomarker assessments, and the coefficients of variation in the hormones across batches were relatively low, suggesting precise assessment of the marker. Finally, this study is the first to evaluate long-term clinical outcomes such as PCa-specific mortality in relation to prediagnostic sex hormone levels.
Conclusions
We found no association between prediagnostic circulating sex hormones and lethal PCa or total mortality. Prior studies that observed an adverse prognosis for patients with metastatic PCa and low androgen levels may reflect an effect of the cancer itself, possibly mediated through suppression of pituitary gonadotropins. Although likely not etiologic, pretreatment hormone levels may nonetheless have clinical utility in risk stratification and prognostication, and further prospective studies are needed to investigate this area.
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